| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Aβ vaccines were developed for the treatment of Alzheimer’s disease. However, clinical trial of active immunization of Aβ peptides showed that 6% of patients suffered from meningoencephalitis. It is thought that the cause of meningoencephalitis may be mainly due to the CD4+ T cells reactive to Aβ. We found new function of SPARC/osteonectin, extracellular cysteine-rich matrix protein as immune-suppressant, and we tried to suppress inflammation under the conditions of Aβ peptide-active immunization and transfer of Aβ－reactive encephalitogenic T cells to APP transgenic mice by SPARC/osteonectin. SPARC/osteonectin suppressed infiltrations of lymphocytes into the brain and also down-regulated the expression of inflammatory cytokines such as TNF-α.
|
